A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT)

作者：Wang, Xiaobing; Zhi, Xiuyi; Yang, Zhaogang; Tian, Haimei; Li, Yanfen; Li, Mo; Zhao, Wenya; Zhang, Chao; Wang, Teng; Liu, Jing; Shen, Di; Zheng, Cuining; Zhao, Dan; Yang, Sheng; Qi, Jun; Xin, Hongwu; Stojadinovic, Alexander; Avital, Itzhak; Lee, L. James; Rao, Jianyu; Zhang, Wei^*

来源：Oncotarget, 2017, 8(28): 45345-45355.

DOI：10.18632/oncotarget.17477

• lung cancer
• biomarker
• early detection
• MIC-1
• screening

Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.

• 出版日期2017-7-11
• 单位北京协和医学院; 长江大学; 首都医科大学; 中国医学科学院北京协和医院